miltefosine has been researched along with Abnormalities, Drug-Induced in 2 studies
miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin
miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.
Abnormalities, Drug-Induced: Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Miltefosine was originally formulated and registered as a topical treatment for cutaneous cancers." | 6.43 | Development of miltefosine as an oral treatment for leishmaniasis. ( Engel, J; Sindermann, H, 2006) |
| "Future issues that need to be addressed for miltefosine are efficacy against non-Indian visceral leishmaniasis, efficacy in HIV-coinfected patients, efficacy against the many forms of cutaneous and mucosal disease, effectiveness under clinical practice conditions, generation of drug resistance and the need to provide a second antileishmanial agent to protect against this disastrous event, and the ability to maintain reproductive contraceptive practices under routine clinical conditions." | 4.83 | Miltefosine: issues to be addressed in the future. ( Berman, J; Bryceson, AD; Croft, S; Engel, J; Gutteridge, W; Karbwang, J; Sindermann, H; Soto, J; Sundar, S; Urbina, JA, 2006) |
| "Miltefosine was originally formulated and registered as a topical treatment for cutaneous cancers." | 2.43 | Development of miltefosine as an oral treatment for leishmaniasis. ( Engel, J; Sindermann, H, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sindermann, H | 2 |
| Engel, J | 2 |
| Berman, J | 1 |
| Bryceson, AD | 1 |
| Croft, S | 1 |
| Gutteridge, W | 1 |
| Karbwang, J | 1 |
| Soto, J | 1 |
| Sundar, S | 1 |
| Urbina, JA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacokinetics of Miltefosine in Children and Adults: Implications for the Treatment of Cutaneous Leishmaniasis in Colombia.[NCT01462500] | Phase 4 | 60 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for miltefosine and Abnormalities, Drug-Induced
| Article | Year |
|---|---|
Development of miltefosine as an oral treatment for leishmaniasis.
Topics: Abnormalities, Drug-Induced; Administration, Oral; Animals; Antineoplastic Agents; Antiprotozoal Age | 2006 |
Miltefosine: issues to be addressed in the future.
Topics: Abnormalities, Drug-Induced; Antiprotozoal Agents; Drug Resistance; Female; Forecasting; HIV Infecti | 2006 |